Index

• New Mental Health Company Led by Consumer Brand Industry Veterans to Revolutionize Mental Health Care Delivery for Seniors
• Elucidata Raises $16 Million Series A to Reimagine AI Infrastructure for the Life Sciences Industry
• Prime Medicine spells out IPO plans for ‘word processor’ of gene editing
• RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital
• Provider search firm Kyruus buys patient engagement company Epion Health
• AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner
• Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi
• Centivo names Jim Foreman Chairman of the Board of Directors
• Latchel Closes $16.7 Million to Enhance Resident Services and Maintenance Workflow
• Vitalxchange Joins Buoy Health’s Marketplace to Provide Special Needs and Disability Parenting Solutions
• Morgan Health Announces New Investment in Centivo
• Eleos Expands Leadership Team with R&D, Finance Hires
• Protenus Recognized as a Top Healthcare Compliance Provider
• WelbeHealth Becomes First Program of All-Inclusive Care for the Elderly (PACE) Provider to Convert to Public Benefit Company Status
• Kyruus Announces Paul Merrild as Company’s First President
• Protenus is Top-Performing Solution in KLAS Drug Diversion Monitoring 2022 Report
• Snapdocs and STRATMOR Group Collaborate to Advance Borrower Experience Research
• Equip Publishes Study Showing Virtual Treatment is Highly Effective for Eating Disorders as Company Expands to 50 States
• Sondermind -The Company Redesigning Behavioral Health For Patients And Therapists
• Immuneel Therapeutics raises $15 million in funding
• Insilico Medicine appoints Dr. Feng Ren as co-CEO
• Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
• Vendr Raises $150MM Series B to Help CFOs Reduce Software Expense
• As their first clinical data test looms, global AI player Insilico bumps up a GSK vet to co-CEO in charge of development
• Has Denali found a way to correct gene mutations linked to Parkinson’s? Possibly, but questions remain
• PROXIMIE RAISES $80 MILLION IN SERIES C FUNDING TO ACCELERATE PRODUCT EXPANSION OF FULL-SERVICE CONNECTED SURGICAL PLATFORM
• Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits
• Big names, big backers: David Baker joins OrbiMed, F-Prime, Khosla and others as protein-ligand biotech launches
• Exclusive: Medical AI startup Owkin just secured $80 million as it gears up to enhance drug trials with the pharmaceutical giant Bristol Myers Squibb
• Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits
• Ontrak Health and Eleos Announce AI Integration Partnership to Support Care for Ontrak Members
• Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
• MediKarma Selects 1upHealth as its Interoperability Partner to Help Patients Acquire Their Medical Records from Hospital EMRs
• Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
• Sana Biotechnology ditches California manufacturing plans in bid to save $100M
• Sana Biotechnology ditches California manufacturing plans in bid to save $100M
• 1upHealth Selected by NCQA As Partner in Digital Quality Solutions Pilot
• SpectrumAi, an LA startup centered on autism, raised $9M in seed funding
• Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
• Apotea Deploys RightPick™ 3 Item-Handling System from RightHand Robotics™ to Expedite Operations for Consumers
• Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
• Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit
• Lenders One® Adds Snapdocs as a Preferred eClosing Provider
• WellAir Brings Clean Air Technology to Brandywine Realty Trust Properties
• Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
• AppliedVR Partners with Kernel to Measure Brain Activity Changes Before, During, and After Virtual Reality (VR) Treatment of Chronic Pain
• Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
• Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
• NodThera Announces Clinical Progress for Lead NLRP3 Inflammasome Inhibitors and Candidate Selection of Novel Brain-Penetrant Compound
• Singular Genomics Announces Formation of Scientific Advisory Board
• Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
• Rallybio wades into Sanofi storeroom for $3M rare disease deal
• Invetx raises $60.5 million to make long-lasting antibody therapies for cats and dogs
• Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
• How cell & gene therapy startups can warm up to investors in this “biotech nuclear winter”
• Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
• Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
• AppliedVR taps Komodo Health to prove out its VR therapeutic for chronic pain
• WellAir Announces Kari Dixon as President and Chief Executive Officer
• Wellframe Addresses the Caregiver Crises Through an Expanded Program Aimed to Assist 250,000 Members by 2025
• Cytek Biosciences Appoints Todd Garland Chief Commercial Officer
• These fast, cheap tests could help us coexist with covid
• 1upHealth Announces SQL on FHIR® to Easily Ask Hard Questions of Healthcare FHIR® Data and Make Timely Real-World Decisions
• Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy
• ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
• MedCity Pivot Podcast: A conversation with Buoy Health’s chief medical officer
• Artemis Health Launches New Solution to Improve Evaluation and Optimization of Point Solutions
• Eleos Health and Zero Suicide Institute Join Forces to Incorporate Best Practices for Suicide Prevention Into Eleos’ Platform
• Turnstone Biologics Announces Executive Leadership Appointments
• Protenus Granted New Patent ‘Methods and Systems for Analyzing Accessing of Drug Dispensing Systems’
• Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
• Whatfix Acquires Leap.is to Expand Mobile Capabilities
• OTA Insight Acquires Kriya RevGEN, Adding Market-Leading Hotel Portfolio & Chain Revenue Intelligence Solution To Commercial Platform
• Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
• Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
• Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
• PROOF DIAGNOSTICS SUBMITS REQUEST FOR EMERGENCY USE AUTHORIZATION SEEKING FIRST APPROVAL OF CRISPR-BASED MOLECULAR POINT-OF-CARE COVID-19 TEST
• Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
• Doceree Closes $11 Million Series A Funding Round Led by F-Prime Capital
• Eleos Health Raises $20M to Unlock In-Session Behavioral Health Voice Data
• Kyruus Welcomes Gail Airasian as General Manager of Emerging Markets as the Company Expands Its Platform to Serve the Broader Digital Health Market
• TraceLink Announces Product Availability Intelligence, Enabling Manufacturers to Predict Drug Shortages up to 90 Days in Advance with Greater Than 80% Accuracy
• HealthTap Joins Buoy Health’s Navigation Initiative to Match More People with the Right Health Care
• Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
• Ivenix to be Acquired by Fresenius Kabi
• Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets
• AmplifyMD Raises $23 Million to Improve Patient Access to Specialty Care
• Innovent and Lilly Expand Strategic Partnership in Oncology
• WellAir Launches a New Advanced Air Cleaning Device in Europe with Independently Tested Industry Leading 99.9% Effectiveness Against Airborne Pathogens
• AppliedVR Renames Its FDA-approved Virtual Reality Therapeutic ‘RelieVRx’ and Announces Three-month Durability Study Results